Thyroid nodule medical therapy
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
|
Thyroid nodule Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thyroid nodule medical therapy On the Web |
|
American Roentgen Ray Society Images of Thyroid nodule medical therapy |
|
Risk calculators and risk factors for Thyroid nodule medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
The goals of initial therapy of differentiated thyroid cancer (DTC) include:
- To remove the primary tumor, disease that has extended beyond the thyroid capsule, and involved cervical lymph nodes. Completeness of surgical resection is an important determinant of outcome, while residual metastatic lymph nodes represent the most common site of disease persistence=recurrence 8256208 PMC2989453
- 14732779
- To minimize treatment-related morbidity. The extent of surgery and the experience of the surgeon both play important roles in determining the risk of surgical complications
- 9742915
- To permit accurate staging of the disease. Because disease staging can assist with initial prognostication, disease management, and follow-up strategies, accurate postoperative staging is a crucial element in the management of patients with DTC PMC5393522 12016468
- To facilitate postoperative treatment with radioactive iodine, where appropriate. For patients undergoing RAI remnant ablation, or RAI treatment of residual or metastatic disease, removal of all normal thyroid tissue is an important element of initial surgery . Near total or total thyroidectomy also may reduce the risk for recurrence within the contralateral lobe
- 9499265
- 11742318
- 9499265
- To permit accurate long-term surveillance for disease recurrence. Both RAI whole-body scanning (WBS) and measurement of serum Tg are affected by residual normal thyroid tissue. Where these approaches are utilized for long-term monitoring, near-total or totalthyroidectomy is required
- 10365671
- To minimize the risk of disease recurrence and metastatic spread. Adequate surgery is the most important treatment variable influencing prognosis, while radioactive iodine treatment, TSH suppression, and external beam irradiation each play adjunctive roles in at least some patients
12605980
It is recommended to use thryoid hormone in iodine insufficient areas as a treatment for benign thyroid nodules. Thyroid hormone in doses that suppress the serum TSH to subnormal levels may result in a decrease in nodule size and may prevent the appearance of new nodules in regions of the world with borderline low iodine intake but in iodine sufficient areas, there are insufficient evidence of beneficial effect of thyroid hormone treatment for benign thyroid nodules
In pregnant women with FNA that is suspicious for or diagnostic of PTC, consideration could be given to administration of LT4 therapy to keep the TSH in the range of 0.1–1 mU=L
- 19451480
9103951
postoperative RAI remnant ablation
Ablation of the remaining lobe with radioactive iodine has been used as an alternative to completion thyroidectomy
- 12490076
Recombinant human TSH–mediated therapy
Recombinant human TSH–mediated therapy may be indicated in selected patients with underlying comorbidities making iatrogenic hypothyroidism potentially risky, in patients with pituitary disease who are unable to raise their serum TSH, or in patients in whom a delay in therapy might be deleterious. Such patients should be given the same or higher activity that would have been given had they been prepared with hypothyroidism or a dosimetrically determined activityBraga M, Ringel MD, Cooper DS 2001 Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 86:5148–5151
Metastases treatment:
Treatment of endocrine metastases should be based on:
- Size of metastatic lesions (macronodular typically detected by chest radiography; micronodular typically detected by CT; lesions beneath the resolution of CT)
- Avidity for RAI and, if applicable, response to prior RAI therapy
- Stability absence of metastatic lesions
| Metastases | Treatment | ||
|---|---|---|---|
| pulmonary metastases | Micrometastases | RAI therapy, and repeated every 6–12 months as long as disease continues to concentrate RAI and respond clinically, because the highest rates of complete remission are reported in these subgroups | |
| macronodular metastases | RAI and treatment should be repeated when objective benefit is demonstrated (decrease in the size of the lesions, decreasing Tg), but complete remission is not common and survival remains poor. The selection of RAI activity to administer can be made empirically (100–200 mCi) or estimated by lesional dosimetry or dosimetry to limit wholebody retention to 80 mCi at 48 hours and 200 cGy to the red bone marrow. | ||
| brain metastases | Complete surgical resection of CNS metastases should be considered regardless of RAI avidity
CNS lesions that are not amenable to surgery should be considered for external beam irradiation. Whole brain and spine irradiation could be considered if multiple metastases are present. |
||
| bone metastases | Complete surgical resection of isolated symptomatic metastases
RAI therapy of iodine-avid bone metastases |
Pulmonary pneumonitis and fibrosis are rare complications of high-dose radioactive iodine treatment